← All trials
NCT05346666
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2022
- Primary completion
- Sep 20, 2023
- Completion date
- Oct 20, 2023
- First posted
- Apr 26, 2022
- Last posted
- Nov 15, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Damanhour UniversityLead sponsor
- Tanta UniversityCollaborator
- Tanta UniversityCollaborator
- Horus UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.